New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs CJC-1295

Pancragen vs CJC-1295

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Growth Hormone Peptides
CJC-1295
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
Half-Life
Short (minutes); sustained gene-regulatory effects
~30 minutes (No DAC) / 6–8 days (with DAC)
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
100 mcg
Frequency
Daily for 10–30 days
Once daily, before bed
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Sustained increase in growth hormone levels
  • Enhanced muscle growth and strength
  • Improved fat metabolism and body composition
  • Better recovery and tissue repair
  • Increased bone density
  • Enhanced immune function
  • Improved skin quality and collagen production
  • Synergistic GH release when combined with GHRPs like Ipamorelin
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Water retention / puffiness
  • Carpal tunnel syndrome (with prolonged use)
  • Injection site irritation
  • Hunger increase (minor)
  • +1 more
Stacks With